Literature DB >> 10480433

Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow.

T L Holyoake1, F E Nicolini, C J Eaves.   

Abstract

The purpose of this study was to develop a simple assay for quantitating transplantable human lymphomyeloid stem cells (competitive repopulating units [CRU]) to enable comparison among the numbers and types of progeny generated in NOD/ SCID mice by such cells from different ontologic sources. Sub-lethally irradiated NOD/SCID mice were transplanted with varying numbers of CD34+ cell-enriched suspensions of human fetal liver, cord blood, or adult marrow cells. The types and numbers of human cells present in the marrow of the mice were measured 6 to 8 weeks later using flow cytometry, in vitro progenitor assays, and secondary transplant endpoints. Frequencies of human CRU obtained by limiting dilution analysis of mice repopulated 6 to 8 weeks posttransplant were the same when the lymphoid and myeloid progeny of CRU were both detected by specific immunophenotypic endpoints as when in vitro myeloid progenitor assays were used to detect CRU myelopoietic activity. The average output per injected CRU of very primitive cells (CD34(+)CD38(-) cells, LTC-IC, and secondary CRU) was found to be highest for fetal liver CRU and progressively decreased (up to >100-fold) for ontologically older CRU. In contrast, the average output of mature cells was highest for cord blood CRU and lowest for fetal liver CRU, despite equivalent production of intermediate progenitors. Differences in the relative numbers of mature lymphoid, myeloid, and erythroid progeny produced by CRU from different ontologic sources were also seen. Finally, evidence of a transplantable human lymphoid-restricted cell present throughout ontogeny was obtained. A simpler and easier assay for enumerating transplantable human stem cells with lymphomyeloid reconstituting activity has been described, and its specificity and sensitivity validated. The use of this assay has revealed ontogeny-associated differences in a variety of functional attributes of human stem cells proliferating and differentiating in an in vivo, but xenogeneic, setting.

Entities:  

Mesh:

Year:  1999        PMID: 10480433     DOI: 10.1016/s0301-472x(99)00078-8

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  52 in total

1.  Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

Authors:  H Glimm; W Eisterer; K Lee; J Cashman; T L Holyoake; F Nicolini; L D Shultz; C von Kalle; C J Eaves
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  High-level beta-globin expression and preferred intragenic integration after lentiviral transduction of human cord blood stem cells.

Authors:  Suzan Imren; Mary E Fabry; Karen A Westerman; Robert Pawliuk; Patrick Tang; Patricia M Rosten; Ronald L Nagel; Philippe Leboulch; Connie J Eaves; R Keith Humphries
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 3.  Cord blood stem cells for hematopoietic transplantation.

Authors:  Anfisa Stanevsky; Avichai Shimoni; Ronit Yerushalmi; Arnon Nagler
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

4.  Single-Cell RNA-Seq Mapping of Human Thymopoiesis Reveals Lineage Specification Trajectories and a Commitment Spectrum in T Cell Development.

Authors:  Justin Le; Jeong Eun Park; Vi Luan Ha; Annie Luong; Sergio Branciamore; Andrei S Rodin; Grigoriy Gogoshin; Fan Li; Yong-Hwee Eddie Loh; Virginia Camacho; Sweta B Patel; Robert S Welner; Chintan Parekh
Journal:  Immunity       Date:  2020-06-16       Impact factor: 31.745

5.  Isolation and therapeutic potential of human haemopoietic stem cells.

Authors:  Andrew D Clark; Heather G Jørgensen; Joanne Mountford; Tessa L Holyoake
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

6.  RAG2-/- gamma(c)-/- mice transplanted with CD34+ cells from human cord blood show low levels of intestinal engraftment and are resistant to rectal transmission of human immunodeficiency virus.

Authors:  Ursula Hofer; Stefan Baenziger; Mathias Heikenwalder; Erika Schlaepfer; Nadine Gehre; Stephan Regenass; Thomas Brunner; Roberto F Speck
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

Review 7.  Optimizing autologous cell grafts to improve stem cell gene therapy.

Authors:  Nikoletta Psatha; Garyfalia Karponi; Evangelia Yannaki
Journal:  Exp Hematol       Date:  2016-04-19       Impact factor: 3.084

8.  Short-term repopulating cells with myeloid potential in human mobilized peripheral blood do not have a side population (SP) phenotype.

Authors:  Marlene Fischer; Manfred Schmidt; Silke Klingenberg; Connie J Eaves; Christof von Kalle; Hanno Glimm
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

9.  Expansion of engrafting human hematopoietic stem/progenitor cells in three-dimensional scaffolds with surface-immobilized fibronectin.

Authors:  Qi Feng; Chou Chai; Xue-Song Jiang; Kam W Leong; Hai-Quan Mao
Journal:  J Biomed Mater Res A       Date:  2006-09-15       Impact factor: 4.396

10.  Expansion of human SCID-repopulating cells under hypoxic conditions.

Authors:  Guénahel H Danet; Yi Pan; Jennifer L Luongo; Dominique A Bonnet; M Celeste Simon
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.